The "final voyage" of the Endeavor stent.

The “final” 5-year outcomes of combined trials with the Endeavor zotarolimus-eluting stent (E-ZES) by Kandzari et al. (1), published in this issue of JACC: Cardiovascular Interventions, might be considered a companion to the Kirtane et al. (2) publication in the issue last month of JACC: Cardiovascular Interventions, which reported on the “final” 5-year follow-up of the ENDEAVOR IV (A Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions) study. Both papers represent an opportunity to place the long-term clinical results of the Endeavor stent in perspective for the here-and-now.